WALTHAM, Mass. — Thermo Fisher Scientific has unveiled new integrated solutions designed to speed up the development of biologic therapeutics, offering biotech and pharmaceutical companies a faster path to Investigational New Drug (IND) applications. Leveraging an enhanced platform technology and a new high-yield CHO K-1 cell line, the company now offers the potential to reduce preclinical development timelines from 13 months to just nine months.
The newly introduced CHO K-1 cell line delivers protein expression levels of up to 8 grams per liter, providing greater stability and productivity across preclinical and commercial stages. This advancement aims to support biopharmaceutical companies of all sizes in accelerating biologics development while navigating complex preclinical processes.
“By prioritizing speed to market and simplification of complex processes, Thermo Fisher is enabling a new era of biologics drug development,” said Jennifer Cannon, president of commercial operations for pharma services at Thermo Fisher Scientific. She emphasized the growing need for efficient, end-to-end cell line development capabilities, particularly among emerging biotech firms and established pharmaceutical companies.
At the core of Thermo Fisher’s approach is its “start here, stay here” model, which allows clients to remain with a single provider throughout the entire clinical development journey. By offering an integrated suite of services, the company eliminates the need for multiple vendors, helping customers streamline procurement strategies and reduce operational complexity.
Through its Accelerator™ Drug Development program, Thermo Fisher combines its Contract Development and Manufacturing Organization (CDMO), Contract Research Organization (CRO), and bioprocessing services into a unified offering. This approach provides customizable manufacturing, clinical research, supply chain management, and bioprocessing capabilities, designed to optimize drug development from candidate selection to commercialization.
The new CHO K-1 cell line and broader platform enhancements are part of Thermo Fisher’s commitment to delivering consistent, scalable support across the drug development lifecycle. With these tools, the company aims to help biopharma clients advance life-saving therapies to patients more quickly and efficiently.
